Revolution Medicines, Inc. (NASDAQ: RVMD) Q3 2024 Earnings Call Transcript November 6, 2024 Revolution Medicines, Inc. misses on earnings expectations. Reported EPS is $-0.94 EPS, expectations were ...

Phase 3 pivotal trial underway evaluating RMC-6236 in patients with metastatic pancreatic ductal adenocarcinoma (PDAC), supported by compelling ...

Based on early Phase I/II trial data, Tango has decided to end enrollment in a study of TNG908 and focus resources on more promising drugs in its pipeline.

Despite the potential in oncology, BNTX's current valuation is high relative to its non-COVID revenue prospects, warranting a ...

Lisata Therapeutics, Inc. (Nasdaq: LSTA), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, and Valo ...

This includes clinical evaluation of TNG462 as a monotherapy and in multiple combinations of both targeted and standard of care agents to begin in 1H 2025, in preparation for registrational trials in ...

Merus’ zenocutuzumab is nearing FDA approval, and petosemtamab shows promise. Learn why MRUS stock could rise as the company ...

The SITC posters will be available on ImCheck's corporate website after the poster sessions have been opened.

Phase 3 registrational trials evaluating petosemtamab in combination with pembrolizumab in 1L and petosemtamab monotherapy in 2/3L r/m HNSCC ...

Adding pembrolizumab to adjuvant chemotherapy in the first-line setting improved disease-free survival (DFS) in patients with high-risk endometrial cancer who have mismatch repair–deficient ...

According to phase 3 study results, the combination of pembrolizumab ... pancreatic ductal adenocarcinoma Results from the phase 2b HERIZON-BTC-01 trial presented at ASCO reveal positive efficacy and ...